Article Text

Download PDFPDF
Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology
  1. E. E. Kim
  1. Division of Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, Houston, TX
  1. Address correspondence and reprint requests to: E. Edmund Kim, MD, Department of Nuclear Medicine, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 59, Houston, TX 77030-4009. Email: ekim{at}


The advent of positron emission tomography (PET) and PET/computed tomography (CT) now enables us to detect metabolically active gynecologic cancers with greater accuracy than was possible with anatomic imagings. Fluorine-18 fluorodeoxyglucose PET has been useful in differentiation of malignant from benign lymph nodes, and residual or recurrent cancers from post-treatment changes. PET/CT produces additional information for the diagnosis and tissue biopsy as well as radiotherapy planning. This paper reviews the principle and clinical utility of PET and PET/CT in the diagnosis, staging, recurrence, therapeutic response as well as prognosis of gynecologic cancers.

  • gynecologic cancer
  • PET
  • PET/ CT

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.